Richard Martin is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 14 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1155 E Paris Ave SE
Ste 100
Grand Rapids, MI 495468368
Telephone
616-459-8088Provider last certified this registry record 30 Jun 2021.
Clinical trials
- Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
- Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma
Sponsor: National Jewish Health
- Promotion of Breastfeeding Intervention Trial
Sponsor: Harvard Pilgrim Health Care
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20211 payment
- Janssen Biotech, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.6%Folate Analog Metabolic Inhibitor22.3%Methotrexate98%Methotrexate Sodium2%Part D<11 patientsTNF inhibitor8.8%Enbrel Sureclick49%Humira(Cf) Pen21%Enbrel20%Adalimumab-Adaz(Cf) Pen7%Humira(Cf)4%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
29%Corticosteroid19.1%Prednisone100%Part D≥229 patientsAntidiarrheal microorganisms9%Folic Acid100%Part D≥107 patients+ 1 more class in this area
Nervous system
17.6%Opioid Agonist9.2%Tramadol Hcl95%Tramadol Hcl-Acetaminophen5%Part D<11 patientsGabapentinoids3.2%Gabapentin100%Part D≥39 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”